| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SLC13A3 |
| Uniprot No | Q8WWT9 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-602 aa |
| 活性数据 | MAALAAAAKKVWSARRLLVLLFTPLALLPVVFALPPKEGRCLFVILLMAVYWCTEALPLSVTALLPIVLFPFMGILPSNKVCPQYFLDTNFLFLSGLIMASAIEEWNLHRRIALKILMLVGVQPARLILGMMVTTSFLSMWLSNTASTAMMLPIANAILKSLFGQKEVRKDPSQESEENTAAVRRNGLHTVPTEMQFLASTEAKDHPGETEVPLDLPADSRKEDEYRRNIWKGFLISIPYSASIGGTATLTGTAPNLILLGQLKSFFPQCDVVNFGSWFIFAFPLMLLFLLAGWLWISFLYGGLSFRGWRKNKSEIRTNAEDRARAVIREEYQNLGPIKFAEQAVFILFCMFAILLFTRDPKFIPGWASLFNPGFLSDAVTGVAIVTILFFFPSQRPSLKWWFDFKAPNTETEPLLTWKKAQETVPWNIILLLGGGFAMAKGCEESGLSVWIGGQLHPLENVPPALAVLLITVVIAFFTEFASNTATIIIFLPVLAELAIRLRVHPLYLMIPGTVGCSFAFMLPVSTPPNSIAFASGHLLVKDMVRTGLLMNLMGVLLLSLAMNTWAQTIFQLGTFPDWADMYSVNVTALPPTLANDTFRTL |
| 分子量 | 93.2 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人SLC13A3蛋白的3篇假设性参考文献示例(注：文献信息为模拟生成，供参考)：
1. **文献名称**：*SLC13A3 Promotes Tumor Metastasis via Dicarboxylate Transport in Renal Cell Carcinoma*
**作者**：Zhang L, et al.
**摘要**：研究通过重组SLC13A3蛋白体外功能实验，发现其介导的二羧酸转运增强了肾癌细胞线粒体代谢，促进侵袭和化疗耐药，提示其作为肿瘤治疗靶点的潜力。
2. **文献名称**：*Structural Insights into the Substrate Specificity of Human SLC13A3 Sodium-Coupled Transporter*
**作者**：Chen X, et al.
**摘要**：利用重组表达于HEK293细胞的SLC13A3蛋白进行冷冻电镜结构解析，揭示了该蛋白底物结合域的构象变化及钠离子协同转运机制。
3. **文献名称**：*SLC13A3 Deficiency Exacerbates Diabetic Kidney Disease through Dysregulated Glutamate Metabolism*
**作者**：Wang Y, et al.
**摘要**：通过构建重组SLC13A3蛋白模型，结合基因敲除小鼠实验，阐明其在肾脏谷氨酸重吸收中的作用，缺失导致糖尿病肾病中代谢紊乱和纤维化加重。
4. **文献名称**：*High-Throughput Screening Identifies Novel Inhibitors of SLC13A3 for Potential Therapeutic Use*
**作者**：Kim S, et al.
**摘要**：基于重组SLC13A3蛋白的体外转运活性检测平台，筛选出小分子抑制剂，并验证其对代谢性疾病相关病理表型的改善作用。
**注**：以上文献为示例性内容，实际文献需通过数据库(如PubMed、Web of Science)检索确认。
Recombinant human SLC13A3 protein is a sodium-coupled dicarboxylate transporter belonging to the solute carrier family 13 (SLC13). This transmembrane protein facilitates the uptake of dicarboxylates, such as succinate, α-ketoglutarate, and citrate, across cellular membranes by coupling their transport with sodium ions. SLC13A3 is predominantly expressed in the kidneys, brain, liver, and placenta, where it plays critical roles in metabolic homeostasis, energy production, and intermediary metabolism. It contributes to regulating cellular energy balance by providing tricarboxylic acid (TCA) cycle intermediates and influencing fatty acid synthesis. Dysregulation of SLC13A3 has been implicated in metabolic disorders, neurological conditions, and cancer progression. Recombinant SLC13A3 is typically produced using heterologous expression systems (e.g., mammalian or insect cells) for functional studies, structural analysis, or drug screening. Its activity is modulated by pH, substrate availability, and signaling pathways, making it a target for therapeutic interventions in diseases linked to mitochondrial dysfunction or abnormal citrate transport. Current research focuses on elucidating its transport mechanism, tissue-specific roles, and potential as a biomarker or drug target for metabolic syndromes and renal pathologies.
×
